277 related articles for article (PubMed ID: 30356906)
1. Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling.
Bazhin AV; von Ahn K; Fritz J; Werner J; Karakhanova S
Front Immunol; 2018; 9():2129. PubMed ID: 30356906
[TBL] [Abstract][Full Text] [Related]
2. CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling.
Xiu W; Luo J
BMC Immunol; 2021 Jan; 22(1):3. PubMed ID: 33407095
[TBL] [Abstract][Full Text] [Related]
3. Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3.
Hayakawa T; Yaguchi T; Kawakami Y
Cancer Sci; 2020 Dec; 111(12):4326-4335. PubMed ID: 33006786
[TBL] [Abstract][Full Text] [Related]
4. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms.
Planès R; BenMohamed L; Leghmari K; Delobel P; Izopet J; Bahraoui E
J Virol; 2014 Jun; 88(12):6672-89. PubMed ID: 24696476
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression on tolerogenic APCs is controlled by STAT-3.
Wölfle SJ; Strebovsky J; Bartz H; Sähr A; Arnold C; Kaiser C; Dalpke AH; Heeg K
Eur J Immunol; 2011 Feb; 41(2):413-24. PubMed ID: 21268011
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade.
Peng Q; Qiu X; Zhang Z; Zhang S; Zhang Y; Liang Y; Guo J; Peng H; Chen M; Fu YX; Tang H
Nat Commun; 2020 Sep; 11(1):4835. PubMed ID: 32973173
[TBL] [Abstract][Full Text] [Related]
9. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
10. Mesenteric lymph node CD11b
Shiokawa A; Kotaki R; Takano T; Nakajima-Adachi H; Hachimura S
Immunology; 2017 Sep; 152(1):52-64. PubMed ID: 28423181
[TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmette-Guérin Induces PD-L1 Expression on Antigen-Presenting Cells via Autocrine and Paracrine Interleukin-STAT3 Circuits.
Copland A; Sparrow A; Hart P; Diogo GR; Paul M; Azuma M; Reljic R
Sci Rep; 2019 Mar; 9(1):3655. PubMed ID: 30842561
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-22 attenuates double-stranded RNA-induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism.
Seki N; Kan-O K; Matsumoto K; Fukuyama S; Hamano S; Tonai K; Ota K; Inoue H; Nakanishi Y
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):242-248. PubMed ID: 29032197
[TBL] [Abstract][Full Text] [Related]
13. ERK/p38 MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets.
Karakhanova S; Meisel S; Ring S; Mahnke K; Enk AH
Eur J Immunol; 2010 Jan; 40(1):254-66. PubMed ID: 19830728
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
15. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
16. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
17. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.
Llopiz D; Ruiz M; Infante S; Villanueva L; Silva L; Hervas-Stubbs S; Alignani D; Guruceaga E; Lasarte JJ; Sarobe P
Oncotarget; 2017 Jan; 8(2):2659-2671. PubMed ID: 27926522
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
19. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.
Selenko-Gebauer N; Majdic O; Szekeres A; Höfler G; Guthann E; Korthäuer U; Zlabinger G; Steinberger P; Pickl WF; Stockinger H; Knapp W; Stöckl J
J Immunol; 2003 Apr; 170(7):3637-44. PubMed ID: 12646628
[TBL] [Abstract][Full Text] [Related]
20. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8
Liu X; Wu X; Cao S; Harrington SM; Yin P; Mansfield AS; Dong H
Sci Rep; 2016 Nov; 6():36722. PubMed ID: 27824138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
